Merck KGaA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0O14.IL | KRK.WA | 002720.KS | 1795.TW | MERK.JK | 3933.HK | |
|---|---|---|---|---|---|---|
| Market cap | 69.64B | 33.00B | 70.36B | 44.76B | 1.58T | 15.37B |
| P/E (TTM) | 21.3 | 18.6 | — | 11.8 | 4.8 | 28.9 |
| Forward P/E | — | — | — | 7.1 | — | 11.3 |
| Price/book | 2.5 | 12.6 | — | 1.9 | 1.7 | 0.8 |
| Dividend yield | 1.48% | 3.61% | 0.89% | 1.61% | 8.02% | 6.47% |
| 1-year change | +34.87% | +22.70% | −20.94% | −42.88% | +10.65% | −41.08% |
| Today | +1.18% | −0.18% | −1.63% | +5.66% | +2.92% | +6.41% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 0O14.IL news ›Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites…
Merck KGaA bets on RNAi with $1.3B Silence buyout
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug. Merck KGaA CEO Kai Beckmann described the transaction as part of an effort to “transform our pipeline…
Merck KGaA makes noise in hematology with $1.1B Silence buy
Germany’s Merck KGaA is making a commotion in the rare disease space with the $1.1 billion acquisition of RNA specialist Silence Therapeutics and the biotech’s Phase 3 asset for polycythemia vera divesiran. The deal gives Merck KGaA “an…
Head to Head Analysis: Merck KGaA (OTCMKTS:MKKGY) and Ono Pharmaceutical (OTCMKTS:OPHLF)
Posted by Defense World Staff on Oct 25th, 2026 Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) and Merck KGaA (OTCMKTS:MKKGY – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the…
Rx Rundown: Merck KGaA, GSK, Hansoh Pharmaceutical and more
Check out this week’s medical marketing news, dealmaking and industry chatter. Merck KGaA said it would acquire Silence Therapeutics in an all-cash deal valued at approximately $1.3 billion. Hansoh Pharmaceutical subsidiaries entered into…
Europe Viral Vector Purification Resins Market Is Going to Boom |Merck KGaA, Sartorius AG
Worldwide Market Reports has published its latest research study on the Europe Viral Vector Purification Resins Market offering an extensive evaluation of the industry from 2026 to 2033 The report presents valuable insights into market…
Merck KGaA entered into definitive agreement to acquire Silence Therapeutics plc for $1.2 billion.
Merck KGaA entered into definitive agreement to acquire Silence Therapeutics plc for $1.2 billion on October 18, 2026. The purchase price of $20 per ADS in cash, with each ADS representing three... Merck KGaA (XTRA:MRK) entered into…
Merck KGaA to Spend $1.3bn on Silence Therapeutics
Merck KGaA (-0.83%, at EUR143.10) announced that it has signed a definitive agreement to acquire British biotechnology company Silence Therapeutics, which specializes in developing therapies based on small interfering RNAs (siRNAs). The…
More from 1 other outlet
Merck KGaA to Buy London-based Silence Therapeutics for $1.3 Billion
Published on 10/19/2026 at 08:44 am EDT Merck: Operational resilience over the years, cannot be overlooked September 04, 2026 at 08:34 am EDT Merck KGaA: From 19th-century cocaine to tomorrow's AI chips Merck CEO on US Business, Life…
Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA
Merck KGaA is to buy Silence Therapeutics plc for $1.3B cash at $20/ADS (130% premium). Click for a look at SLN and see why I am downgrading it. - Silence Therapeutics plc is being acquired by Merck KGaA in an all-cash $1.3B deal, offering…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com11
- openpr.com6
- seekingalpha.com2
- stocktitan.net2
- tradingview.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 37 articles, not a forecast.